Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 2Recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 1774Neoplasms 1501Carcinoma, Non-Small-Cell Lung 1043Prostatic Neoplasms 957Colorectal Neoplasms 878Lung Neoplasms 800Pancreatic Neoplasms 572Carcinoma, Hepatocellular 542Leukemia, Myeloid, Acute 541Stomach Neoplasms 512Ovarian Neoplasms 507Neoplasm Metastasis 496Multiple Myeloma 495Recurrence 413Melanoma 386Squamous Cell Carcinoma of Head and Neck 370Brain Neoplasms 362Uterine Cervical Neoplasms 361Head and Neck Neoplasms 355Esophageal Neoplasms 312Precursor Cell Lymphoblastic Leukemia-Lymphoma 310Lymphoma 305Endometrial Neoplasms 304Triple Negative Breast Neoplasms 299Glioblastoma 298Rectal Neoplasms 280Urinary Bladder Neoplasms 264Sarcoma 264Hematologic Neoplasms 264Colonic Neoplasms 254

Interventions

trifluridine tipiracil drug combination 1tipiracil 1irinotecan sucrosofate 1Trifluridine 1Ramucirumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Metastatic Gastric Adenocarcinoma × Clear all
NCT05927857 2026-04-09

Ramucirumab (Cyramza), Nal-IRI (ONIVYDE) and Trifluridine/Tipiracil (Lonsurf) in Second Line Metastatic Gastric Cancer .

National Health Research Institutes, Taiwan

Phase 1/2 Recruiting
45 enrolled
Gastrointestinal

Metastatic Gastric Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡